Certara (NASDAQ:CERT) Coverage Initiated by Analysts at Rothschild & Co Redburn

Rothschild & Co Redburn started coverage on shares of Certara (NASDAQ:CERT) in a research report released on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $10.00 price target on the stock.

A number of other brokerages have also weighed in on CERT. Barclays dropped their price objective on Certara from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. KeyCorp increased their price objective on shares of Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Certara from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. BMO Capital Markets assumed coverage on shares of Certara in a report on Thursday, November 13th. They issued a “market perform” rating and a $9.00 price target on the stock. Finally, Redburn Partners set a $10.00 target price on Certara in a research note on Friday. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.82.

Certara Stock Up 7.6%

Shares of Certara stock traded up $0.61 during trading on Friday, hitting $8.64. 2,362,798 shares of the stock were exchanged, compared to its average volume of 2,539,916. Certara has a 12-month low of $8.02 and a 12-month high of $15.69. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of 123.43 and a beta of 1.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The firm’s 50-day moving average price is $11.30 and its 200 day moving average price is $11.14.

Certara (NASDAQ:CERT) last issued its earnings results on Thursday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.03. The business had revenue of $104.62 million during the quarter, compared to analysts’ expectations of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same quarter in the prior year, the business posted $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. As a group, analysts forecast that Certara will post 0.28 earnings per share for the current fiscal year.

Insider Activity at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the sale, the insider owned 73,979 shares in the company, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.33% of the stock is currently owned by corporate insiders.

Institutional Trading of Certara

Hedge funds have recently made changes to their positions in the company. CIBC Bancorp USA Inc. acquired a new stake in shares of Certara during the third quarter valued at about $2,844,000. Morningstar Investment Management LLC bought a new stake in Certara in the third quarter valued at about $1,598,000. Wasatch Advisors LP raised its stake in Certara by 28.6% during the third quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock valued at $212,608,000 after buying an additional 3,865,455 shares in the last quarter. Parkman Healthcare Partners LLC lifted its holdings in Certara by 10.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 551,850 shares of the company’s stock worth $6,744,000 after buying an additional 51,850 shares during the last quarter. Finally, London Co. of Virginia grew its position in shares of Certara by 5.6% in the 3rd quarter. London Co. of Virginia now owns 1,554,991 shares of the company’s stock worth $19,002,000 after acquiring an additional 82,283 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.